Filing Analysis
EDAP TMS SA announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release and a corresponding conference call on May 7, 2026.
Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The press release was issued and the conference call was held on May 7, 2026.
- The information was furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
EDAP TMS SA has satisfied conditions to draw down a €12.0 million second tranche (Tranche B) of its €36.0 million credit facility with the European Investment Bank (EIB). As part of the transaction, the company issued 1,116,244 warrants to the EIB with an exercise price of €3.23 per share.
Red Flags
- Potential dilution of over 1.1 million shares from the exercise of Tranche B warrants.
- Increase in direct financial obligations by €12.0 million.
Key Facts
- Drawdown of €12.0 million from a total €36.0 million facility established on October 17, 2025.
- Tranche B borrowings have a five-year maturity from the late April 2026 disbursement date.
- Interest on the Tranche B borrowings is deferred and payable only at the maturity date.
- Issuance of 1,116,244 Tranche B warrants to the EIB to purchase ordinary shares at €3.23 per share.
- The warrants were issued in an unregistered sale relying on Section 4(a)(2) exemption.
EDAP TMS SA announced its financial results for the fourth quarter ended December 31, 2025, via a press release and scheduled conference call.
Key Facts
- The filing reports financial results for the fiscal quarter ended December 31, 2025.
- The report was filed on March 25, 2026.
- The company issued a press release (Exhibit 99.1) and held a conference call to discuss the results.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
EDAP TMS SA announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 18, 2026. The company furnished its investor presentation materials as an exhibit to the filing for public access.
Key Facts
- The company is presenting at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 18, 2026.
- Investor presentation materials were furnished as Exhibit 99.1.
- The presentation is being webcast via the company's investor relations website.
- The filing is made under Item 7.01 (Regulation FD Disclosure).